Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Current Leases (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Current Leases data on record, last reported at $4.2 million in Q3 2025.

  • For Q3 2025, Current Leases rose 16.32% year-over-year to $4.2 million; the TTM value through Sep 2025 reached $4.2 million, up 16.32%, while the annual FY2024 figure was $3.7 million, 17.46% up from the prior year.
  • Current Leases reached $4.2 million in Q3 2025 per GLUE's latest filing, up from $4.1 million in the prior quarter.
  • Across five years, Current Leases topped out at $4.2 million in Q3 2025 and bottomed at $2.7 million in Q2 2023.
  • Average Current Leases over 3 years is $3.5 million, with a median of $3.5 million recorded in 2024.
  • Peak YoY movement for Current Leases: surged 30.15% in 2024, then increased 15.55% in 2025.
  • A 3-year view of Current Leases shows it stood at $3.2 million in 2023, then increased by 17.46% to $3.7 million in 2024, then grew by 14.19% to $4.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $4.2 million in Q3 2025, $4.1 million in Q2 2025, and $3.9 million in Q1 2025.